This cohort was evaluated because, in a previous phase II study, lurbinectedin had shown antitumor activity in patients with advanced breast cancer and germline BRCA1/2 pathogenic variants: overall response rate (ORR) was 41% and median overall survival (OS) was 20.0 months compared to 9% and 12.5 months, respectively, in patients with BRCA1/2 wild-type or unknown status.14 This evidence concerns the gene BRCA1 and breast carcinoma.